TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06003335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular message delivery
Description: Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular message delivery
Description: Regular messages will be sent regularly to each participant over the 12-week study period. As personalisation is a core process in enabling behavioural change, the intervention content, frequency, and timing of the messages will be based on the participants' self-care needs and preferences, which will be surveyed at baseline. If no specific preferences are provided, we will plan the message delivery to decrease in frequency over time as this trend has shown the highest effectiveness in existing studies. The format of messages will be mainly texts, but other formats such as pictures and voice messages will also be considered for addition to the content library to suit a wide range of preferences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat-type support message delivery
Description: Chat-based support will be given to the participants in addition to the regular message delivery. Instant messaging will be used to communicate directly with the participants. We plan to recruit 10 student RAs who have been trained in the delivery of interactive instant messages (IMs) to provide chat-type support to encourage increased physical activity and interaction. Participants will be invited to set physical activity goals and action plans through the chat-type support. Participants will receive a personalised summary of their physical activity weekly and will be encouraged to reflect on this through a real-time chat (around 5 minutes). They will also be encouraged to establish a plan of how they can adjust their physical activity goal going forward. When addressing the participants' queries or any ethical concerns, the student RAs will be instructed to immediately report to the Principal Applicant and supervisors who are experienced and trained research nurses.
Study: NCT05539963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Antibiotics
Description: Participants will receive Antibiotics per site-specific requirements.
Study: NCT05507216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily in the morning with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily in the morning with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily in the morning with food
Study: NCT06027463

Intervention type: PROCEDURE
Intervention: Head and neck vascular recanalization
Description: Head and neck vascular recanalization
Study: NCT05123105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1) cupping therapy
Description: The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2) control test (no intervention)
Description: The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3) ischemic compression
Description: The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
Study: NCT04836910

Intervention type: OTHER
Intervention: Dietary recommendations
Description: Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day.

Intervention type: DRUG
Intervention: Oral contraceptive pills
Description: Hormonal treatment

Intervention type: DRUG
Intervention: Metformin
Description: Insulin resistance treatment
Study: NCT05447078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immulina TM
Description: Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immulina TM
Description: Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immulina TM
Description: Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
Study: NCT05715346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV102 1.0%
Description: Oxymetazoline ophthalmic gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV102 2.0%
Description: Oxymetazoline ophthalmic gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle ophthalmic gel
Study: NCT05861453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epeleuton
Description: Participants will receive 2000mg Epeleuton (DS102) capsules twice daily.
Study: NCT06465368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07220060
Description: PF-07220060 given as tablet by mouth twice a day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole given as tablet by mouth once a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: Letrozole given as tablet by mouth once a day for 14 days
Study: NCT05060484

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCT1000
Description: HPV vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCT1000
Description: HPV vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil®9
Description: HPV vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil®
Description: HPV vaccine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: adjuvent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: adjuvent
Study: NCT06349200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 432 Hz music
Description: Music tuned to the 432 Hz frequency, as compared with other frequencies, has the advantage of providing utter calm, pleasure, and peace to its listeners. It has proven to be effective for reducing stress and improving sleep quality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binaural beats
Description: Binaural beats are defined as the sound that is born when two sounds of constant intensity but different frequencies are presented to both ears separately. The resultant sound perceived in the brain has a single tone and a frequency equivalent to the difference between the frequencies of the carrier sounds

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: White noise
Description: White noise is a type of random sound characterized by equal intensity across all frequencies within the audible range, resulting in a steady, uniform sound similar to the static from a television or radio tuned to an unused frequency.
Study: NCT05456945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure application
Description: Acupressure will be applied to the UB32 point

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocher
Description: Shotblocher will be administered during injection
Study: NCT04332198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological test
Description: dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
Study: NCT05585853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
Study: NCT04848974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC
Study: NCT06553469

Intervention type: DEVICE
Intervention: sacral neuromodulation
Description: After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which the sacral nerve stimulation electrode component was implanted. After the electrode was implanted, it was tested for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with Phase II and was evaluated by the researcher as suitable for implantation, Phase II (permanent implantation phase) treatment was performed, during which the sacral nerve stimulation pulse generator component was implanted
Study: NCT04997421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes
Description: Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
Study: NCT04857372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAG933
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAG933
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAG933
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAG933
Description: Capsule
Study: NCT05746429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Receive mobile CBT
Study: NCT04997421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes
Description: Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
Study: NCT05152914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerliponase Alfa
Description: Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Study: NCT04964284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhTSH
Description: rhTSH (0.9 mg) was administered intramuscularly (IM) once daily (qd) for 2 days. Twenty-four hours following the second dose of rhTSH

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodine (131I)
Description: Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodine (131I)
Description: Patients were given an ablative dose of 131I (30 mCi±1.5 mCi).
Study: NCT05746429

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Receive mobile CBT
Study: NCT06475651

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
Study: NCT05746429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Undergo active tDCS
Study: NCT06475651

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.

Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
Study: NCT05022875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthcare CEO app- for experimental app intervention
Description: The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Healthcare CEO app-for control app intervention
Description: consists of 2 interfaces: CEO's profile, Health Tracking.
Study: NCT06148389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1301 subcutaneous injection
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Study: NCT05746429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Attend virtual meetings and focus groups

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo Administration
Description: Undergo sham tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06148389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1301 subcutaneous injection
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1301 subcutaneous injection
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1301 subcutaneous injection
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1301 subcutaneous injection
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Study: NCT05669001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Study Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAC
Description: Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPA
Description: Immunosuppression Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA
Description: Immunosuppression Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Immunosuppression Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Immunosuppression Therapy
Study: NCT06268639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification
Description: The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.